University of Natural Resources and Life Sciences, Vienna (BOKU) - Research portal

Logo BOKU Resarch Portal

Selected Publication:

Kallolimath, S; Sun, L; Palt, R; Stiasny, K; Mayrhofer, P; Gruber, C; Kogelmann, B; Chen, Q; Steinkellner, H.
(2021): Highly active engineered IgG3 antibodies against SARS-CoV-2
P NATL ACAD SCI USA. 2021; 118(42), e2107249118 FullText FullText_BOKU

Monoclonal antibodies (mAbs) that efficiently neutralize SARSCoV-2 have been developed at an unprecedented speed. Notwithstanding, there is a vague understanding of the various Ab functions induced beyond antigen binding by the heavy-chain constant domain. To explore the diverse roles of Abs in SARS-CoV-2 immunity, we expressed a SARS-CoV-2 spike protein (SP) binding mAb (H4) in the four IgG subclasses present in human serum (IgG1-4) using glyco-engineered Nicotiana benthamiana plants. All four subclasses, carrying the identical antigen-binding site, were fully assembled in planta and exhibited a largely homogeneous xylose- and fucose-free glycosylation profile. The Ab variants ligated to the SP with an up to fivefold increased binding activity of IgG3. Furthermore, all H4 subtypes were able to neutralize SARS-CoV-2. However, H4-IgG3 exhibited an up to 50-fold superior neutralization potency compared with the other subclasses. Our data point to a strong protective effect of IgG3 Abs in SARS-CoV-2 infection and suggest that superior neutralization might be a consequence of cross-linking the SP on the viral surface. This should be considered in therapy and vaccine development. In addition, we underscore the versatile use of plants for the rapid expression of complex proteins in emergency cases.
Authors BOKU Wien:
Kallolimath Somanath
Kogelmann Benjamin
Palt Roman
Steinkellner Herta
Sun Lin

Find related publications in this database (Keywords)
engineered IgG3
-based expression
virus neutralization

© BOKU Wien Imprint